 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || CID-103 / CASI, Precision Autoimmune Therap
Enrollment closed, Enrollment change: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 2, 2023
P1, N=10, Active, not recruiting, Sponsor: CASI Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=60 --> 10
- ||| CID-103 / CASI, Precision Autoimmune Therap
Enrollment open: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 3, 2021
P1, N=60, Recruiting, Sponsor: CASI Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=60 --> 10 Not yet recruiting --> Recruiting
- | CID-103 / CASI
Journal: HS-GC-IMS with PCA to analyze volatile flavor compounds across different production stages of fermented soybean whey tofu. (Pubmed Central) - Mar 2, 2021
A PCA based on the signal intensity of the detected volatile compounds revealed effective differentiation of samples from different stages into comparatively independent spaces. These results showed that the flavor fingerprints of the samples from different stages of FSWT production can be successfully built using HS-GC-IMS and PCA based on the detected volatile compounds.
- ||| CID-103 / CASI, Precision Autoimmune Therap
New P1 trial: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 16, 2021
P1, N=60, Not yet recruiting, Sponsor: CASI Pharmaceuticals, Inc.
- Darzalex IV (daratumumab) / J&J, CID-103 / CASI
[VIRTUAL] CID-103, an Anti-CD38 Monoclonal Antibody Demonstrates Decreased RBC Binding and Decreased Interference with Pretransfusion Test Methods () - Sep 27, 2020 - Abstract #AABB2020AABB_331;
Gel column testing was the most sensitive to interference giving weak variable reactivity, and Ortho AHG was less likely to detect the microscopic binding to RBCs. No interference was seen using automated Tango and IH1000.